The combined use of cyclophosphamide and G-CSF is considered optimal, as cyclophosphamide reduces the risk of MS exacerbation induced by G-CSF and contributes to reducing T-cell numbers during apheresis [17]. This evidence concerns the gene CSF3 and myeloid sarcoma.